VRX-480773

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 535110

CAS#: N/A

Description: VRX-480773 is a Novel Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI).

Chemical Structure

img
VRX-480773
CAS# N/A
Instruction

Theoretical Analysis

MedKoo Cat#: 535110
Name: VRX-480773
CAS#: N/A
Chemical Formula: C23H19BrClN5O3S2
Exact Mass: 590.98
Molecular Weight: 592.911
Elemental Analysis: C, 46.59; H, 3.23; Br, 13.48; Cl, 5.98; N, 11.81; O, 8.10; S, 10.81

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: VRX-480773; VRX 480773; VRX480773

IUPAC/Chemical Name: 2-[[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide

InChi Key: JMAGRGYNUBAGRG-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H19BrClN5O3S2/c24-22-28-29-23(34-12-21(31)27-19-9-7-14(11-18(19)25)35(26,32)33)30(22)20-10-8-15(13-5-6-13)16-3-1-2-4-17(16)20/h1-4,7-11,13H,5-6,12H2,(H,27,31)(H2,26,32,33)

SMILES Code: O=C(NC1=CC=C(S(=O)(N)=O)C=C1Cl)CSC2=NN=C(Br)N2C3=C4C=CC=CC4=C(C5CC5)C=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 592.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Wan ZY, Tao Y, Wang YF, Mao TQ, Yin H, Chen FE, Piao HR, De Clercq E, Daelemans D, Pannecouque C. Hybrid chemistry. Part 4: Discovery of etravirine- VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem. 2015 Aug 1;23(15):4248-4255. doi: 10.1016/j.bmc.2015.06.048. Epub 2015 Jun 27. PMID: 26162497.


2: Zhang Z, Xu W, Koh YH, Shim JH, Girardet JL, Yeh LT, Hamatake RK, Hong Z. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2007 Feb;51(2):429-37. doi: 10.1128/AAC.01032-06. Epub 2006 Nov 20. PMID: 17116677; PMCID: PMC1797749.


3: Li W, Li X, De Clercq E, Zhan P, Liu X. Discovery of potent HIV-1 non- nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif. Eur J Med Chem. 2015 Sep 18;102:167-79. doi: 10.1016/j.ejmech.2015.07.043. Epub 2015 Jul 26. PMID: 26276432.


4: Wan ZY, Yao J, Tao Y, Mao TQ, Wang XL, Lu YP, Wang HF, Yin H, Wu Y, Chen FE, De Clercq E, Daelemans D, Pannecouque C. Discovery of piperidin-4-yl- aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem. 2015 Jun 5;97:1-9. doi: 10.1016/j.ejmech.2015.04.050. Epub 2015 Apr 27. PMID: 25935383.


5: Jochmans D, Anders M, Keuleers I, Smeulders L, Kräusslich HG, Kraus G, Müller B. Selective killing of human immunodeficiency virus infected cells by non- nucleoside reverse transcriptase inhibitor-induced activation of HIV protease. Retrovirology. 2010 Oct 15;7:89. doi: 10.1186/1742-4690-7-89. PMID: 20950436; PMCID: PMC2974656.


6: Wan ZY, Yao J, Mao TQ, Wang XL, Wang HF, Chen WX, Yin H, Chen FE, De Clercq E, Daelemans D, Pannecouque C. Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue. Eur J Med Chem. 2015 Sep 18;102:215-22. doi: 10.1016/j.ejmech.2015.08.007. Epub 2015 Aug 7. PMID: 26276435.